There were no double-digit losers, but with OPTI:Optibiotix dropping 6%, SKIN:SkinBiotherapeutics dropping 9% and KIBO:Kibo Mining dropping 5% it could easily have been a red week. However, this week's only double-digit riser and Share of the Week was AMYT:Amryt Pharma which soared 22%, taking paper profits to £2,445 and making it my 2nd best performer after IQE:IQE. The 4p rise that lifted it to 26p was worth over £1,300, and with brokers suggesting 60p+ as target price, this could quite quickly add another £14,000 over the next few years.
I ought to give GVC:GVC Holdings a mention too. A 7% rise this week saw the price go to 811p, so with my original purchase price of 420p this has nearly doubled. If I hadn't bedded it into my ISA and taken a chunk of the profits from paper to real, this would be up there competing with AMYT:Amryt Pharma for 2nd best performer, and it's paid out £142 in dividends too.
The gap is back!
The ISA and share accounts look like this
| Weekly Change | |||
| Portfolio cost | £42,839.83 | +£269.69 | |
| Portfolio sell value (bid price - commission) | £44,208.79 | (+3.2%) | +£827.47 |
| Potential profits | £6,082.61 | +£1,586.90 | |
| Yr 2 Dividends | £458.94 | +£0 | |
| Yr 2 Profit from sales | £2,401.06 | +£0 | |
| Yr 2 Average monthly cash profit | £291.60 | -£7.11 | |
| Yr 2 Avg annual % of current portfolio cost | 8.2% | ||
| Total Dividends | £1,126.87 | +£0 | |
| Total Profit from sales | £6.241.32 | +£0 | |
| Average monthly cash profit | £335.83 | -£3.61 | |
| (Sold stocks profit + Dividends - Fees / Months) | |||
| Avg annual % of current portfolio cost | 9.4% |
I added £269 to buy some more CMCL:Caledonia Mining before the share consolidation. Potential profits were up a massive £1,586 thanks to AMYT:Amryt Pharma and GVC:GVC Holdings, but half of that was zapped by the increased losses I mentioned above. No sales or dividends, so a slight tick down in performance and I'm still conscious I need to get the average back above 10%.
After the panic of 2 weeks ago, the recovery has been most satisfying, and don't forget there's the £1,100 loss from the AFG:Aquatic Food disaster lost in the middle of that lot somewhere, causing barely a ripple in the lines.
The SIPP looks like this after week 78
| Weekly Change | |||
| Portfolio cost | £17,468.71 | +£0 | |
| Portfolio sell value (bid price - commission) | £19,787.19 | (+13.3%) | -£315.77 |
| Potential profits | £3,082.20 | -£277.42 | |
| Yr 2 Dividends | £0 | +£0 | |
| Yr 2 Profit from sales | £1,596.81 | +£0 | |
| Yr 2 Average monthly cash profit | £258.98 | -£10.36 | |
| Yr 2 Avg annual % of current portfolio cost | 17.8% | ||
| Total Dividends | £413.19 | +£0 | |
| Total Profit from sales | £3,946.67 | +£0 | |
| Average monthly cash profit | £237.01 | -£3.08 | |
| (Sold stocks profit + Dividends - Fees / Months) | |||
| Avg annual % of current portfolio cost | 16.3% |
The pension didn't have the protection of AMYT:Amryt Pharma and so the drop in OPTI:Optibiotix did a lot of damage. There were small drops in the loss-making shares too, which dragged the portfolio value down despite another tick up for IQE:IQE.
If I can maintain this gap for a while I'll be happy.
The dreaded trading account looks like this after week 44
| Weekly Change | |||
| Portfolio cost | £986.03 | +£0 | |
| Cash | £79.63 | +£0 | |
| Portfolio sell value (bid price - commission) | £835.79 | (-15.2%) | -£38.10 |
| Potential profits | £0 | +£0 | |
| Dividends | £0 | +£0 | |
| Profit from sales | -£22.85 | +£0 | |
| Average monthly cash profit | -£2.25 | +£0.05 | |
| (Sold stocks profit + Dividends - Fees / Months) | |||
| Avg annual % of current portfolio cost | -2.87% |
What an unmitigated disaster. Nearly a year and I've managed to make a loss from sales thanks to pulling my JLP:Jubilee Platinum shares out of this account into my ISA and the other 2 absolutely refuse to get into profit while I sit impotently waiting for something interesting to do. I'm such a shit trader! Glad this experiment is with a small percentage of my savings.
Next week is a short week with the bank holiday, and none of my shares are due to report so it could be a quiet one as we await the general election. It would be nice if AMYT:Amryt Pharma could do an IQE:IQE and slowly creep upwards, as that will protect my buffer from volatility elsewhere. There's a risk of profit taking though, as the FAST:Fastnet Equity reverse takeover price was 24p so the long-term holders that might be feeling impatient could start to bale as we climb towards 30p. In my opinion that would be rather premature, as this company has potential to deliver astounding shareholder value for those invested from the start.
OPTI:Optibiotix continues to perplex. News of contracts coming after the Vitafoods exhibition could give us a boost, and the long-awaited news of free SKIN:SkinBiotherapeutics shares would be most welcome. Murmurings on the bulletin board suggest that the attempts to reward long-term holders over and above day traders are not going to be realised, which is a shame, but I'd really like to know what we're going to get so I can make some decisions on whether to buy any more SKIN:SkinBiotherapeutics shares on the market while they are below my initial buying price.
No comments:
Post a Comment